Richard Finn, MD, from UCLA's Jonsson Comprehensive Cancer Center, discusses the difficulties of treating liver cancer.
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the difficulties of treating liver cancer.
Finn says liver cancer is unique because it occurs with underlying liver disease and cirrhosis. Many drugs in this space have ignored underlying liver disease with the exception of sorafenib, which was the last liver cancer drug to be approved.
Sorafenib continues to be the standard when treating liver cancer because it was developed to minimize the effect of underlying liver disease. In the SHARP trial, Finn says, sorafenib improved the survival rate of patients with liver cancer compared to a placebo.
Since the SHARP trial, there have been many more phase III studies, but no new drugs have demonstrated superiority to sorafenib, Finn says.
Finn thinks that many antiangiogenic multikinase inhibitors could have shown benefit compared with placebo in frontline studies, but as sorafenib is the standard, it has been difficult to improve upon.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More